Rapport Therapeutics, Inc. Common Stock
- RAPP
- NASDAQ
- Biotechnology
- CNS Disorder Therapeutics
- Clinical-Stage Biopharma
$28.60
Today +3.74%Quote Oct 19, 2026, 08:00 PM UTC
−29.30%over the last month
Max drawdown −33.5%From 1-month high −31.0%3 months −32.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
84
Market value
$1.37B
Quote Oct 19
Floor
$28.50
0.4% below price
Resistance
$29.06
1.6% above price
Price vs analyst targets
5 analysts
Lowest target
$50.00Highest target
$75.00
$50.00Highest target
$75.00
- Price $28.60
- Average target $63.75
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 123% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RAPPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free